Regeneron, Teva in deal for pain candidate fasinumab

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will pay Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) $250 million up front in a deal to jointly develop and commercialize Regeneron's pain candidate fasinumab ( REGN475). Regeneron is eligible for $450 million in development and regulatory milestones, plus $1.9 billion in sales milestones.

Fasinumab, a mAb against nerve growth factor (NGF), is in Phase III testing for osteoarthritis (OA) pain and in Phase II testing for chronic low back pain. ...